title: [Treatment results with external radiotherapy in prostate cancer].
abstract: OBJECTIVE
  External irradiation is an accepted curative treatment modality for patients with localized prostatic tumor. The 15-year results in patients treated by radical irradiation alone are presented. The determinant prognostic factors for local tumor control and disease free survival are analyzed.
  
  
  METHODS
  135 patients with a histologically confirmed localized carcinoma of the prostate were treated at our department from May 1972 to January 1998. Fifty patients received Co-60 therapy; the linear accelerator and high energy photons were utilized in the remaining 80 patients. By tumor stage, 53 patients were B1, 49 B2 and 33 C. The mean follow-up was 61 months (range 1-180). Most patients were exposed to localized fields of irradiation; dose ranged from 50-74 Gy, fractionated at a dose of 180-200 cGy/day.
  
  
  RESULTS
  Overall local tumor control was 77% at 5 years and 73% at 15 years, with a disease free survival of 63% and 45% at 5 and 15 years, respectively. Local tumor control at 13 years was 71% for stage B1, 82% for B2 and 70% for C. The disease free survival at 13 years for stages B1, B2 and C were 46%, 49% and 36%, respectively. The BD and MD tumors had a 15-year disease free survival of 48% vs 32% for the PD tumors (p = 0.005). Patients with PSA < or = 20 ng/ml before treatment showed a disease free survival of 87% vs 48% for those with PSA > 20 ng/ml ((p = 0.011). Multivariate analysis showed dose to be a determinant prognostic factor for local tumor control (0.0432); dose and histological grade were determinants for disease free survival (p = 0.029 and 0.033).
  
  
  CONCLUSIONS
  This retrospective study found dose to be a determinant prognostic factor for local tumor control and both dose and histological grade were determinants for disease free survival. Radiotherapy is a therapeutic option for these patients. The results can be enhanced if the dose delivered to the prostate can be increased while maintaining the complication rate within the same ranges.
authors.affiliation: Servicio de Oncología-Radioterápica, Hospital Central de Asturias, Oviedo, España.
authors.forename: P J
authors.initials: PJ
authors.lastname: Prada Gómez
authors.forename: A
authors.initials: A
authors.lastname: Alonso García
authors.forename: M
authors.initials: M
authors.lastname: Canteli Castañón
authors.forename: L
authors.initials: L
authors.lastname: Olay Gayoso
authors.forename: R
authors.initials: R
authors.lastname: Alonso Pantiga
authors.forename: G J
authors.initials: GJ
authors.lastname: Rijo
authors.forename: R
authors.initials: R
authors.lastname: Rodríguez Fernández
authors.forename: A
authors.initials: A
authors.lastname: Querejeta Recalde
authors.forename: A F
authors.initials: AF
authors.lastname: Castillo
authors.forename: M
authors.initials: M
authors.lastname: Matallanas Bermejo
authors.forename: J
authors.initials: J
authors.lastname: Fernández García
authors.forename: J
authors.initials: J
authors.lastname: Vivanco Parellada
mesh_terms: D000368:Aged; D002277:Carcinoma / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D003037:Cobalt Radioisotopes / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D019583:Dose Fractionation, Radiation; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D011867:Radioisotope Teletherapy / Q000009:adverse effects; D013030:Spain / Q000453:epidemiology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D003037:Cobalt Radioisotopes